Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
暂无分享,去创建一个
C. Sternberg | C. Barrios | I. Davis | C. Szczylik | J. Wagstaff | J. Mardiak | R. Hawkins | P. Salman | D. Roychowdhury | L. Pandite | J. Zarbá | O. Gladkov | Eunsik Lee | Mei Chen | A. Kavina | L. Mccann | L. McCann
[1] A. Kibel. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .
[2] M. Gordon. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .
[3] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[4] Chris Coppin,et al. Immunotherapy for renal cell cancer in the era of targeted therapy , 2008, Expert review of anticancer therapy.
[5] R. Figlin,et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor , 2008 .
[6] T. Wilt,et al. Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.
[7] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[8] M. Gordon,et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .
[9] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[10] M. Neary,et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.
[11] A. Ravaud,et al. Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis , 2007, Cancer.
[12] R. Motzer,et al. Sunitinib efficacy against advanced renal cell carcinoma. , 2007, The Journal of urology.
[13] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[14] P. Lara,et al. Renal cell carcinoma: current status and emerging therapies. , 2007, Cancer treatment reviews.
[15] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[16] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[17] D. V. van Spronsen,et al. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. , 2005, Anti-cancer drugs.
[18] H. Hurwitz,et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors , 2005 .
[19] J. Berlin,et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Ross Camidge,et al. The European Organisation for Research and Treatment of Cancer , 2002 .
[21] R. Rabin,et al. EQ-SD: a measure of health status from the EuroQol Group , 2001, Annals of medicine.
[22] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[23] Mora,et al. The Mainz Classification of Renal Cell Tumors. , 1999, Cancer control : journal of the Moffitt Cancer Center.
[24] M Mazumdar,et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.